@article{dfd17e0b68644e16a0ac84d2c7a41f24,
title = "A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)",
abstract = "To compare the efficacy of one cycle of standard dose cisplatin, etoposide, and ifosfamide (VIP) plus three cycles of high-dose VIP followed by stem-cell infusion [high-dose chemotherapy (HD-CT arm)] to four cycles of standard cisplatin, etoposide, and bleomycin (BEP) in patients with poor-prognosis germ-cell cancer (GCC). Patient and methods: Patients with poor-prognosis GCC were assigned to receive either BEP or VIP followed by HD-CT. To show a 15% improvement in a 1-year failure-free survival (FFS), the study aimed to recruit 222 patients but closed with 137, due to slow accrual.",
keywords = "Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Chorionic Gonadotropin, Cisplatin, Disease-Free Survival, Etoposide, Humans, Ifosfamide, Kaplan-Meier Estimate, L-Lactate Dehydrogenase, Male, Mediastinal Neoplasms, Middle Aged, Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Prognosis, Retroperitoneal Neoplasms, Stem Cell Transplantation, Testicular Neoplasms, Tumor Markers, Biological, Young Adult, alpha-Fetoproteins",
author = "G Daugaard and I Skoneczna and N Aass and {De Wit}, R and {De Santis}, M and H Dumez and S Marreaud and L Collette and Lluch, {J R G} and C Bokemeyer and Schmoll, {H J}",
year = "2011",
month = may,
doi = "10.1093/annonc/mdq575",
language = "English",
volume = "22",
pages = "1054--61",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Elsevier Limited",
number = "5",
}